The Food and Drug Administration is expected to approve GW Pharmaceuticals' (Nasdaq: GWPH) seizure treatment that is made with cannabidiol. The stock price leaped $13.55 to close at $134.13.
Approval expected for GW Pharmaceuticals' product
April 17, 2018 at 17:28 PM EDT
